micronized fenofibrate / Generic mfg. - LARVOL DELTA

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=6 | Terminated | Sponsor: Mayo Clinic | Completed ➔ Terminated; Low Enrollment

Trial termination • Transplantation

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Lindsay Ferguson, MD | Suspended ➔ Recruiting

Enrollment open • Cervical Cancer • Gynecology • Oncology • Solid Tumor

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Suspended | Sponsor: Lindsay Ferguson, MD | Recruiting ➔ Suspended

Trial suspension • Cervical Cancer • Gynecology • Oncology • Solid Tumor

Hypercholesterolemia management in a patient with mitochondrial encephalomyopathy lactic acidosis, and stroke-like episodes (NLA 2025) - "However, one case study in a patient with mitochondrial myopathy due to heteroplasmic mitochondrial DNA missence mutation in MTCO1 gene (m.7671T>A) demonstrated stable CK levels without recurrence of myalgia while taking alirocumab 75 mg every 2 weeks, ezetimibe 10 mg daily, marine omega 3 fatty acids daily, and 145 mg of micronized fenofibrate every 2 days (Cicero et al., 2020)...He had a history of hypercholesterolemia with debilitating myalgias on simvastatin, atorvastatin and rosuvastatin prior to MELAS diagnosis...Ezetimibe 10 mg daily and icosapent ethyl 4 g daily was initiated and well tolerated...Evolocumab 140 mg subcutaneous every 14 days was prescribed and tolerated without side effects...Conclusions This case highlights consideration for MELAS in young adults with stroke-like episodes and demonstrates successful use of non-statin lipid lowering medications to manage hypercholesterolemia. Further research is necessary in this patient population."

Clinical • Cardiovascular • CNS Disorders • Dyslipidemia • Metabolic Disorders • Musculoskeletal Pain • Myositis • Pain

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=5 | Completed | Sponsor: Mayo Clinic | Recruiting ➔ Completed | N=148 ➔ 5

Enrollment change • Trial completion • Hepatology • Transplantation

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Lindsay Ferguson, MD | Not yet recruiting ➔ Recruiting

Enrollment open • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

Fenofibrate in Patients with Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Lindsay Ferguson, MD | Trial completion date: May 2025 ➔ Nov 2026 | Initiation date: Aug 2024 ➔ Nov 2024 | Trial primary completion date: Jan 2025 ➔ Jun 2026

Trial completion date • Trial initiation date • Trial primary completion date • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Lindsay Ferguson, MD | Initiation date: Feb 2024 ➔ Aug 2024

Trial initiation date • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Lindsay Ferguson, MD

New P1 trial • Cervical Cancer • Gynecology • Oncology • Solid Tumor • TP53

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=148 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Feb 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Hepatology • Transplantation

Associates of fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. (PubMed, Diabetes Metab Res Rev) - "Insulin use and sex-specific complications (in men, macrovascular disease; in women, neuropathy) are independently associated with fragility fractures in adults with type 2 diabetes."

Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology • Type 2 Diabetes Mellitus

A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (AHA 2022) - P2 | "These agents have been shown to inhibit SARS-CoV-2 replication in cell culture systems in vitro. We randomly assigned 701 participants with COVID-19 within 14 days of symptom onset to 145 mg of fenofibrate (nanocrystal formulation with dose adjustment for renal function or dose-equivalent preparations of micronized fenofibrate or fenofibric acid) vs. placebo for 10 days, in a double-blinded fashion. Among patients with COVID-19, fenofibrate has no significant effect on various clinically relevant outcomes."

Clinical • Diabetes • Genetic Disorders • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Obesity • Respiratory Diseases • PPARA

Lipid-lowering drugs. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Comparison table: Some lipid-lowering drugs. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

FICsDCD: A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation (clinicaltrials.gov) - P2 | N=148 | Recruiting | Sponsor: Mayo Clinic

New P2 trial • Hepatology • Transplantation

Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Beijing 302 Hospital; N=72 ➔ 0; Trial completion date: Jan 2019 ➔ Sep 2021; Recruiting ➔ Withdrawn; Trial primary completion date: Jan 2019 ➔ Sep 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Fibrosis • Hepatology • Immunology • Primary Biliary Cholangitis

Fenofibrate in Type 2 Diabetes (clinicaltrials.gov) - P4; N=11; Completed; Sponsor: Medical University of South Carolina; Recruiting ➔ Completed; N=40 ➔ 11; Trial completion date: Mar 2021 ➔ Mar 2020; Trial primary completion date: Dec 2020 ➔ Mar 2020

Biomarker • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Content analysis of social and economic issues in Indonesia during the COVID-19 pandemic. (PubMed, Heliyon) - "This is a descriptive quantitative study using a content analysis approach to obtain primary data from 6,376 online news articles published by Antara News from 28 February to 8 April 2020...COVID-19 is not only a global health crisis but also a major labour market and economic crisis that has had a significant impact on society. In conclusion, a broader study is recommended using several publication periods and online media."

Journal • Infectious Disease • Novel Coronavirus Disease

Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia's National General Hospital. (PubMed, Acta Med Indones) - "Data termasuk karakteristik klinis, gejala, komorbiditas, multimorbiditas dan luaran mortalitas pasien.HasilDi populasi pasien lansia (n=44), mayoritas berusia di antara 60-69 tahun (68%), berjenis kelamin laki-laki (66%), dan tidak memiliki riwayat kontak erat dengan pasien COVID-19 sebelumnya (86%)...Atypical COVID-19 presentations are possible in older adults. We postulated that immunosenescence and sex-specific immunoregulatory function play an important role in causing death in this study cohort. Keywords: Clinical Profile, Elderly, Geriatric Patient, COVID-19, Indonesia."

Clinical • Journal • Diabetes • Geriatric Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Oncology

Fenofibrate in Type 2 Diabetes (clinicaltrials.gov) - P4; N=40; Recruiting; Sponsor: Medical University of South Carolina; Trial completion date: Sep 2020 ➔ Mar 2021; Trial primary completion date: Jun 2020 ➔ Dec 2020

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

"Ya Allah gini amat ya ini orang, gw antara pengen marah sm ngakak.. To save my self, I chose lol" (@Mims05783653)

"Negara pioneer dalam penggunaan teknologi ini adalah Amerika Syarikat. Antara bidang terawal y dilaporkan menggunakan teknologi ini ialah Kanser darah dan Penyakit keturunan (Heredity Disiease/Genetic disease). Kalau kenan nak guna teknologi ni, boleh refer @nanostringtech !" (@FathiaTahir)

Lipid Biomarkers for Diabetic Heart Disease (clinicaltrials.gov) - P=N/A; N=104; Recruiting; Sponsor: Washington University School of Medicine; Trial primary completion date: Mar 2017 ➔ Feb 2018

Trial primary completion date • Biosimilar • Cardiovascular • Diabetes • Heart Failure

Lupin receives FDA approval for its New Drug Application for Antara capsules (PRNewswire) - "Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its supplemental New Drug Application (sNDA) for Antara® (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration (FDA)."

sNDA • Atherosclerosis • Dyslipidemia

Type I hypersensitivity reaction as a complication of lepa. (PubMed) - J Basic Clin Pharm - "The observations were erythema, eruptions, and itching. Such case of hypersensitivity is discussed in the present study."

Journal • Biosimilar • Immunology • Inflammation • Pain